---
Today, I’d like to return to my previous topic of reputation management and critically examine a dogmatic belief that underlies many academic and popular texts about corporate ethics. It goes something like this:
“It makes economic sense to pursue ethical goals because consumers reward ethical behavior over the long term.”
It would be comforting to believe this. However, I have found little evidence that this would be the case in any generic sense. I do believe that
1. Expressly non-ethical behavior can pose a severe reputation risk.
What I find problematic is the argument that it always pays to be perceived as more ethical or virtuous than your rivals. Would it not make sense to stay close to the ground, avoid misbehaving but not be the model student either? I do believe, however, that
2. There are contexts in which ethical leadership over competititors.
Some companies invest enormous sums of money in good deeds, as well as in good presentations to promote the public image of being a responsible company. Many pharmaceuticals companies, for instance, have invested large sums in various kinds of virtuous projects. A well-known example is provided by Merck & Company, which has played a major role in treating so-called “river blindness” caused by parasites in sub-Saharan Africa. River blindness is a painful ailment that often leads to permanent loss of vision. Merck & Company has distributed free of charge over 250 million treatments, each of which costs more than one euro (BBC News article “River blindness drug revives village life” 15 September 2002, here). The treatment was discovered by Dr. William Campbell, a veterinary researcher at Merck & Company who was studying parasite-inflicted illnesses in animals. The company developed the treatment in cooperation with the World Health Organization. Sub-Saharan Africa was and still is a poor region. After failing to receive funding from the US government and several other bodies, Merck & Company decided to donate the treatment to everyone in need of it for as long as the disease prevailed. The company has maintained its commitment for over 20 years. (www.merck.com) Swiss pharmaceuticals giant Novartis has been similarly active, donating enormous amounts of medications to developing nations and the poor in 2004. The company invested a total of EUR 440 million in socially responsible projects around the world. These projects had an effect on over 4 million people. Even small deeds count. Novartis Finland sponsors an annual “Community Partnership Day” with the Finnish Federation of the Visually Impaired. The Novartis Finland website describes the project as follows (www.novartis.fi):
“The basic ideology of Community Partnership Day is that company employees donate one-day’s labor for a community project of their choosing. Community Partnership Day is organized by Novartis worldwide and is part of the company’s Corporate Citizenship. Last year over 10,000 Novartis employees in 45 countries participated in Community Partnership Day.”
These examples are inspiring, no doubt. The reason for them being inspiring, however, is that they are exceptions...Read the whole entry and the discussion here.